Hepatitis Monthly

Published by: Kowsar

Liver Fibrosis is Associated with NAFLD Activity Score in Chronic Hepatitis B Patients with Liver Steatosis

Li-Li Wu 1 , 2 , Jing Zhou 3 , Qing-Xian Cai 1 , 2 , Ya-Xin Huang 1 , 2 , Dong-Ying Xie 1 , 2 , Zhi-Liang Gao 1 , 2 and Hong Deng 1 , 2 , *
Authors Information
1 Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
3 Department of Pathology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Article information
  • Hepatitis Monthly: 18 (12); e84182
  • Published Online: December 15, 2018
  • Article Type: Research Article
  • Received: September 11, 2018
  • Revised: November 9, 2018
  • Accepted: November 20, 2018
  • DOI: 10.5812/hepatmon.84182

To Cite: Wu L, Zhou J, Cai Q, Huang Y, Xie D, et al. Liver Fibrosis is Associated with NAFLD Activity Score in Chronic Hepatitis B Patients with Liver Steatosis, Hepat Mon. Online ahead of Print ; 18(12):e84182. doi: 10.5812/hepatmon.84182.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. [PubMed: 26231459].
  • 2. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28 Suppl 1:7-10. doi: 10.1111/jgh.12220. [PubMed: 23855289].
  • 3. Hu YC, Yeh CC, Chen RY, Su CT, Wang WC, Bai CH, et al. Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program. PeerJ. 2018;6. e4297. doi: 10.7717/peerj.4297. [PubMed: 29472994]. [PubMed Central: PMC5817935].
  • 4. Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. Seroprevalence of hepatitis B and C in patients with hemophilia: A single-centre descriptive study. Shiraz E-Med J. 2015;16(7). e24573. doi: 10.17795/semj24573.
  • 5. Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, et al. YMDD motif mutation profile among patients receiving liver transplant due to hepatitis B virus infection with long term lamivudine/immunoglobulin therapy. Hepat Mon. 2015;15(7). e27120. doi: 10.5812/hepatmon.27120v2. [PubMed: 26300928]. [PubMed Central: PMC4539793].
  • 6. European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. [PubMed: 27062661].
  • 7. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: Meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361-7. doi: 10.1111/j.1440-1746.2011.06801.x. [PubMed: 21649726].
  • 8. Yilmaz B, Koklu S, Buyukbayram H, Yalcin K, Korkmaz U, Posul E, et al. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. Afr Health Sci. 2015;15(3):714-8. doi: 10.4314/ahs.v15i3.3. [PubMed: 26957957]. [PubMed Central: PMC4765474].
  • 9. Alizadeh A, Mansour-Ghanaei F, Roozdar A, Joukar F, Sepehrimanesh M, Hojati SA, et al. Laboratory tests, liver vessels color doppler sonography, and fibroscan findings in patients with nonalcoholic fatty liver disease: An observation study. J Clin Imaging Sci. 2018;8:12. doi: 10.4103/jcis.JCIS_93_17. [PubMed: 29692949]. [PubMed Central: PMC5894278].
  • 10. Deng H, Wang CL, Lai J, Yu SL, Xie DY, Gao ZL. Noninvasive diagnosis of hepatic steatosis using fat attenuation parameter measured by fibrotouch and a new algorithm in CHB patients. Hepat Mon. 2016;16(9). e40263. doi: 10.5812/hepatmon.40263. [PubMed: 27822268]. [PubMed Central: PMC5088638].
  • 11. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862-73. doi: 10.1016/j.jhep.2017.06.003. [PubMed: 28642059].
  • 12. Seto WK, Hui RWH, Mak LY, Fung J, Cheung KS, Liu KSH, et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol. 2018;16(4):575-583 e2. doi: 10.1016/j.cgh.2017.09.044. [PubMed: 28970146].
  • 13. Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32(3):667-76. doi: 10.1111/jgh.13536. [PubMed: 27547913].
  • 14. Zheng RD, Chen JN, Zhuang QY, Lu YH, Chen J, Chen BF. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. Int J Med Sci. 2013;10(5):641-6. doi: 10.7150/ijms.5649. [PubMed: 23569427]. [PubMed Central: PMC3619103].
  • 15. Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol. 2007;41(5):513-7. doi: 10.1097/01.mcg.0000225586.78330.60. [PubMed: 17450036].
  • 16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93. doi: 10.1002/hep.510240201. [PubMed: 8690394].
  • 17. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32(1):3-13. doi: 10.1055/s-0032-1306421. [PubMed: 22418883].
  • 18. Petta S, Camma C, Di Marco V, Macaluso FS, Maida M, Pizzolanti G, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int. 2011;31(4):507-15. doi: 10.1111/j.1478-3231.2011.02453.x. [PubMed: 21382161].
  • 19. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007;132(5):1955-67. doi: 10.1053/j.gastro.2007.03.039. [PubMed: 17484888].
  • 20. Poortahmasebi V, Alavian SM, Keyvani H, Norouzi M, Mahmoodi M, Jazayeri SM. Hepatic steatosis: Prevalence and host/viral risk factors in Iranian patients with chronic hepatitis B infection. Asian Pac J Cancer Prev. 2014;15(9):3879-84. doi: 10.7314/APJCP.2014.15.9.3879. [PubMed: 24935567].
  • 21. Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones. 2012;44(1):35-9. [PubMed: 22451183].
  • 22. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74-80. doi: 10.1002/hep.1840110114. [PubMed: 2295475].
  • 23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. doi: 10.1002/hep.20701. [PubMed: 15915461].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments